From the Guidelines
Manthera should not be used with Ozempic (semaglutide) as there is no FDA-approved medication called "Manthera" for weight loss or diabetes management. Ozempic is an FDA-approved GLP-1 receptor agonist used to treat type 2 diabetes and, under the brand name Wegovy, for chronic weight management. If you're considering weight loss or diabetes medications, consult with a healthcare provider who can prescribe legitimate options like Ozempic (typically starting at 0.25mg weekly, gradually increasing to 1mg or 2mg), Wegovy, or other approved medications, as recommended by recent guidelines 1. The effectiveness of GLP-1 agonists comes from their ability to slow gastric emptying, increase feelings of fullness, and regulate blood sugar by stimulating insulin release when glucose levels are high, with added benefits of reducing cardiovascular events in people with type 2 diabetes who are either at high risk for cardiovascular disease or have cardiovascular disease 1. Always be cautious of unapproved supplements or medications claiming weight loss benefits, as they may contain harmful ingredients or dangerous drug interactions. Some key points to consider when choosing glucose-lowering medications for people with type 2 diabetes and overweight or obesity include:
- Prioritizing medications with beneficial effects on weight, such as GLP-1 receptor agonists (RAs) and a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA (tirzepatide) 1
- Considering the potential benefits and risks of weight management pharmacotherapy, and screening for malnutrition, especially in those who have undergone metabolic surgery or are treated with weight management pharmacologic therapy 1
- Continuing weight management pharmacotherapy beyond reaching weight loss goals to maintain health benefits, and reevaluating therapies if treatment goals are not reached 1. It's also important to note that GLP-1 RA–based medications, such as semaglutide, have demonstrated cardiovascular benefits in persons with obesity, and are recommended for obesity management 1.
From the Research
Manthera and Ozempic
- Manthera is not a recognized medical term, however, Ozempic is a brand name for the medication semaglutide, which is used to treat type 2 diabetes and obesity.
- Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps to lower blood sugar levels and promote weight loss 2, 3, 4.
- The medication has been shown to be effective in reducing HbA1c levels, body weight, and cardiovascular risk factors in patients with type 2 diabetes 2, 3, 5.
- Semaglutide is generally well-tolerated, but common side effects include gastrointestinal disorders such as nausea, vomiting, and diarrhea 3, 6, 5.
- The safety profile of semaglutide is similar to that of other GLP-1 receptor agonists, with no unexpected safety issues arising to date 6.
Efficacy of Semaglutide
- Semaglutide has been shown to be superior to other treatments in reducing HbA1c levels and body weight in patients with type 2 diabetes 3, 5.
- The medication has also been shown to have a favorable effect on cardiovascular risk factors, including systolic blood pressure and lipid profiles 3, 5.
- Semaglutide has been approved for the treatment of obesity, with studies showing significant weight loss and improvements in cardiovascular risk factors 4.
Safety Considerations
- Semaglutide has been associated with an increased risk of gastrointestinal adverse events, including nausea, vomiting, and diarrhea 3, 6, 5.
- The medication has also been associated with an increased risk of biliary disease, including cholelithiasis 6.
- However, the overall safety profile of semaglutide is considered favorable, with no unexpected safety issues arising to date 6.